Nuage Therapeutics is a drug discovery company headquartered at the Parc Científic de Barcelona, Spain. Founded in 2021, we are pioneering a whole new approach to cancer drug discovery by unlocking the therapeutic potential of intrinsically disordered proteins (IDPs), a target class that accounts for the majority of oncogenic transcription factors, but has remained out of reach for conventional drug discovery.
Our mission is to deliver transformational precision therapies for aggressive cancers with limited treatment options by directly targeting the oncogenic transcription factors that drive them.